BioSpace News Archive

Expect to initiate Phase 1a clinical study of BX002 for the treatment of IBD in the third quarter of 2020; pharmacokinetics results expected by the end of 2020

Karuna Therapeutics, Inc., an innovative clinical-stage biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with disabling and potentially fatal neuropsychiatric disorders, announced the appointment of Laurie Olson to its Board of Directors effective August 12, 2020.

Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need, provided a business update and reported financial results for the second quarter of 2020.

Combination of Prexigebersen, Decitabine and Venetoclax Is Expected to Have Several Potential Pathways to Registration

Company plans to advance lead product candidate, AK-OTOF, for the treatment of hearing loss due to mutations in the OTOF gene, to IND submission in 2021 and advance development programs spanning multiple inner ear disorders

Obalon Therapeutics, Inc. announced that it has executed a consulting agreement with Blue Ox Healthcare Partners, LLC, a private equity firm focused on commercial-ready companies bringing technology enabled innovation to healthcare, especially those involved in precision health, healthcare delivery, and affordability.

KAHR Medical today announced the company’s participation in Oppenheimer’s Private Life Sciences Company Call Series taking place virtually August 17-19, 2020.

Xenetic Biosciences, Inc., a biopharmaceutical company focused on advancing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens, reported its financial results for the second quarter ended June 30, 2020 and provided a corporate update.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its offer to acquire all of the ordinary shares of QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) has lapsed. Based on information provided by the settlement agents for the offer, Deutsche Bank Aktiengesellschaft and Amer

Mydecine Innovations Group Inc. (CSE:MYCO) (OTC:MYCOF) (FSE:0NFA) (“Mydecine” or the “Company”), is pleased to announce that NeuroPharm Inc., a company focused on developing unique mental health therapies and approaches for veteran wellness, was recently covered in Forbes for its ground-breaking psilocybin clinical trials for treatment of posttraumatic stress disorder (PTSD). Conducted in collaboration with Leiden University Medical Center of